Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898897504> ?p ?o ?g. }
- W2898897504 endingPage "e531" @default.
- W2898897504 startingPage "e520" @default.
- W2898897504 abstract "Background Standard treatment for untreated advanced-stage follicular lymphoma is rituximab plus chemotherapy. The incidence of histological transformation of follicular lymphoma has been reported only in heterogeneously treated populations and rarely with long-term follow-up. Additionally, the incidence of secondary malignancies after treatment, without high-dose therapy for follicular lymphoma, is largely unknown. The aim of our study was to assess progression-free survival, overall survival, incidence of secondary malignancies, and incidence of histological transformation in a 10-year follow-up analysis of the JCOG0203 trial. Methods In the phase 2–3 randomised JCOG0203 trial, previously untreated patients with stage III or IV indolent B-cell lymphoma, including grades 1–3 follicular lymphoma, from 44 hospital centres in Japan, were randomly assigned (1:1) by use of a minimisation method to receive six cycles of R-CHOP (rituximab [375 mg/m2], given on day 1, plus cyclophosphamide [750 mg/m2], doxorubicin [50 mg/m2], vincristine [1·4 mg/m2, capped at 2·0 mg] given intravenously on day 3, and oral prednisone [100 mg once daily on days 3–7]) every 3 weeks (R-CHOP-21) or every 2 weeks (enabled by mandatory granulocyte-colony stimulating factor administration once daily for 6 days, starting on day 8; R-CHOP-14) without rituximab maintenance. Age, bulky disease (nodal or extranodal mass ≥10 cm in diameter on CT), and institution were used as adjustment factors. Investigators enrolled participants, and assignment to trial groups was done with a computer-assisted randomisation allocation sequence that took place centrally at the Japan Clinical Oncology Group Data Center, without the intervention of investigators. Interventions were not masked for patients or investigators. Data were collected 10 years after enrolment of the last patient. The primary endpoint of the phase 3 part of the study was progression-free survival, and the primary endpoint of the phase 2 part of the study was the proportion of patients who achieved a complete response. Accrual was 4·5 years, and follow-up was 3 years after registration was closed. Data were updated on the cutoff date of Feb 28, 2017. Intention-to-treat analyses (ie, progression-free survival, overall survival, and incidence of secondary malignancies) were predefined, to be done at 10 years after the last patient was enrolled. An additional analysis of the incidence of histological transformation was defined 15 years after the protocol, on May 8, 2017, in a supplementary analysis plan, and assessed at 10 years after the last patient was enrolled. Follow-up is ongoing. This trial is registered with ClinicalTrials.gov, number NCT00147121. Findings Between Sept 1, 2002, and Feb 28, 2007, 300 patients were enrolled, and 149 (50%) were assigned to the R-CHOP-21 group and 151 (50%) were assigned to the R-CHOP-14 group. After eligibility was assessed, one patient was excluded from the R-CHOP-21 group. 10-year progression-free survival was not different between groups (R-CHOP-21 33%, 95% CI 25–41; R-CHOP-14 39%, 31–47; hazard ratio 0·89, 95% CI 0·67–1·17). In 248 patients with grade 1–3a follicular lymphoma, progression-free survival was 39% (33–45) at 8 years and 36% (30–42) at 10 years. The cumulative incidence of histological transformation was 3·2% (95% CI 1·5–6·0) at 5 years, 8·5% (5·4–12·4) at 8 years, and 9·3% (6·1–13·4) at 10 years after enrolment. At 10 years, the cumulative incidence of secondary malignancies was 8·1% (5·1–12·0) and the cumulative incidence of haematological secondary malignancies was 2·9% (1·3–5·5). Interpretation R-CHOP is a viable option for first-line treatment in patients with newly diagnosed advanced follicular lymphoma. Clinicians choosing a first-line treatment for patients with follicular lymphoma should be cautious of secondary malignancies caused by immunochemotherapy and severe complications of infectious diseases in the long-term follow-up—both of which could lead to death. Funding National Cancer Center and Ministry of Health, Labour and Welfare of Japan." @default.
- W2898897504 created "2018-11-09" @default.
- W2898897504 creator A5002320368 @default.
- W2898897504 creator A5002493998 @default.
- W2898897504 creator A5003748585 @default.
- W2898897504 creator A5004550999 @default.
- W2898897504 creator A5007350320 @default.
- W2898897504 creator A5008217392 @default.
- W2898897504 creator A5008746762 @default.
- W2898897504 creator A5009149908 @default.
- W2898897504 creator A5013112899 @default.
- W2898897504 creator A5013490553 @default.
- W2898897504 creator A5013827002 @default.
- W2898897504 creator A5015436878 @default.
- W2898897504 creator A5015509689 @default.
- W2898897504 creator A5017360616 @default.
- W2898897504 creator A5018463402 @default.
- W2898897504 creator A5018968800 @default.
- W2898897504 creator A5019239117 @default.
- W2898897504 creator A5020757111 @default.
- W2898897504 creator A5021699640 @default.
- W2898897504 creator A5021889272 @default.
- W2898897504 creator A5022970809 @default.
- W2898897504 creator A5024057178 @default.
- W2898897504 creator A5024413745 @default.
- W2898897504 creator A5025614828 @default.
- W2898897504 creator A5027036852 @default.
- W2898897504 creator A5027118202 @default.
- W2898897504 creator A5028457340 @default.
- W2898897504 creator A5030377462 @default.
- W2898897504 creator A5033546080 @default.
- W2898897504 creator A5034245076 @default.
- W2898897504 creator A5034798001 @default.
- W2898897504 creator A5035118858 @default.
- W2898897504 creator A5035323117 @default.
- W2898897504 creator A5036000764 @default.
- W2898897504 creator A5036112859 @default.
- W2898897504 creator A5036324396 @default.
- W2898897504 creator A5037105339 @default.
- W2898897504 creator A5038965321 @default.
- W2898897504 creator A5039257959 @default.
- W2898897504 creator A5039282643 @default.
- W2898897504 creator A5039588117 @default.
- W2898897504 creator A5041678137 @default.
- W2898897504 creator A5041701016 @default.
- W2898897504 creator A5042608347 @default.
- W2898897504 creator A5042777060 @default.
- W2898897504 creator A5043392594 @default.
- W2898897504 creator A5044048807 @default.
- W2898897504 creator A5044099774 @default.
- W2898897504 creator A5045089480 @default.
- W2898897504 creator A5045468227 @default.
- W2898897504 creator A5045993454 @default.
- W2898897504 creator A5046522890 @default.
- W2898897504 creator A5047791149 @default.
- W2898897504 creator A5048061147 @default.
- W2898897504 creator A5049002681 @default.
- W2898897504 creator A5049376343 @default.
- W2898897504 creator A5049465924 @default.
- W2898897504 creator A5052429078 @default.
- W2898897504 creator A5052467301 @default.
- W2898897504 creator A5053036587 @default.
- W2898897504 creator A5053647194 @default.
- W2898897504 creator A5053689963 @default.
- W2898897504 creator A5054830507 @default.
- W2898897504 creator A5055192416 @default.
- W2898897504 creator A5055831731 @default.
- W2898897504 creator A5056635560 @default.
- W2898897504 creator A5056662507 @default.
- W2898897504 creator A5056681640 @default.
- W2898897504 creator A5057175176 @default.
- W2898897504 creator A5057386384 @default.
- W2898897504 creator A5059167270 @default.
- W2898897504 creator A5059948213 @default.
- W2898897504 creator A5060157655 @default.
- W2898897504 creator A5060770246 @default.
- W2898897504 creator A5060866250 @default.
- W2898897504 creator A5061841627 @default.
- W2898897504 creator A5062419119 @default.
- W2898897504 creator A5063243902 @default.
- W2898897504 creator A5064816147 @default.
- W2898897504 creator A5067223666 @default.
- W2898897504 creator A5067816264 @default.
- W2898897504 creator A5068557516 @default.
- W2898897504 creator A5068935539 @default.
- W2898897504 creator A5069675532 @default.
- W2898897504 creator A5069720125 @default.
- W2898897504 creator A5069870157 @default.
- W2898897504 creator A5070702322 @default.
- W2898897504 creator A5072163593 @default.
- W2898897504 creator A5072772886 @default.
- W2898897504 creator A5074447395 @default.
- W2898897504 creator A5075358038 @default.
- W2898897504 creator A5077687541 @default.
- W2898897504 creator A5078705233 @default.
- W2898897504 creator A5078852881 @default.
- W2898897504 creator A5081301408 @default.
- W2898897504 creator A5082279921 @default.